Market capitalization | $22.48m |
Enterprise Value | $17.81m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.22 |
P/S ratio (TTM) P/S ratio | 1.54 |
P/B ratio (TTM) P/B ratio | 2.89 |
Revenue growth (TTM) Revenue growth | 0.54% |
Revenue (TTM) Revenue | $14.58m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Vivos Therapeutics Inc forecast:
2 Analysts have issued a Vivos Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 15 15 |
1%
1%
|
|
Gross Profit | 8.27 8.27 |
2%
2%
|
|
EBITDA | -12 -12 |
35%
35%
|
EBIT (Operating Income) EBIT | -13 -13 |
34%
34%
|
Net Profit | -13 -13 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.
Head office | United States |
CEO | R. Huntsman |
Employees | 114 |
Founded | 2016 |
Website | www.vivos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.